Chiron's preemptive patent moves
Chiron Corp.'s gene therapy deal with Viagene Inc., like the deal announced earlier in the month with Pasteur Sanofi covering HIV-1 and HIV-2 immunodiagnostics, illustrates CHIR's aggressive use of patent strategy to gain dominant advantages in key areas of interest.
CHIR and Viagene agreed to collaborate in the development of gene therapy for the prevention and treatment of cancer and chronic infectious diseases such as hepatitis and HIV.
The deal combines CHIR's work in retroviral vectors and prodrug activation with Viagene's direct administration retroviral vector technology.
The collaboration will avoid possible patent battles and strengthen the proprietary positions